Cho, Young Min; Koo, Bo Kyung; Son, Ho Young; Lee, Kwang Woo; Son, Hyun Shik; Choi, Dong Seop; Kim, Bo Wan; Kim, Yong Ki; Lee, Moon Kyu; Lee, Hyun Chul; Min, Kyung Wan; Chung, Min Young; Baek, Hong Sun; Kim, Youngkun; Yoo, Hyung Joon; Park, Kyong Soo; Lee, Hong Kyu
Journal of diabetes investigation
2010Aug ; 1 ( 4 ) :143-8.
PMID : 24843423
ÀúÀÚ »ó¼¼Á¤º¸
Cho, Young Min - Department of Internal Medicine, Seoul National University College of Medicine.
Koo, Bo Kyung - Department of Internal Medicine, Seoul National University College of Medicine.
Son, Ho Young - Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea.
Lee, Kwang Woo - Department of Internal Medicine, The Catholic University of Korea.
Son, Hyun Shik - Department of Internal Medicine, Uijeongbu St. Mary Hospital, The Catholic University of Korea.
Choi, Dong Seop - Department of Internal Medicine, Korea University College of Medicine, Seoul.
Kim, Bo Wan - Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu.
Kim, Yong Ki - Department of Internal Medicine, Pusan National University College of Medicine, Busan.
Lee, Moon Kyu - Department of Internal Medicine, SungKyunKwan University School of Medicine.
Lee, Hyun Chul - Department of Internal Medicine, Yonsei University College of Medicine.
Min, Kyung Wan - Department of Internal Medicine, Eulji University School of Medicine, Seoul.
Chung, Min Young - Department of Internal Medicine, Chonnam National University College of Medicine, Gwangju.
Baek, Hong Sun - Department of Internal Medicine, Chonbuk National University College of Medicine, Jeonju.
Kim, Youngkun - Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon.
Yoo, Hyung Joon - Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
Park, Kyong Soo - Department of Internal Medicine, Seoul National University College of Medicine.
Lee, Hong Kyu - Department of Internal Medicine, Seoul National University College of Medicine.
ABSTRACT
Aims/Introduction:? Mitiglinide is the newest drug in the meglitinide family. It increases the early-phase insulin release through rapid association-dissociation kinetics in the pancreatic β cells. The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown. MATERIALS AND
METHODS: ? We carried out a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who showed inadequate glycemic control with metformin monotherapy. Subjects with glycated hemoglobin (HbA1c) >7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met?+?Mit) or metformin plus placebo (Met?+?Pcb).
RESULTS: ? Compared with the Met?+?Pcb group, the Met?+?Mit group showed a greater reduction in HbA1c (-0.7?±?0.6%vs-0.4?±?0.7%, P?=?0.002), fasting plasma glucose (-0.77?±?1.76?mmol/L vs-0.05?±?1.60?mmol/L, P?=?0.015) and 2-h postprandial glucose (-3.76?±?3.57?mmol/L vs-0.84?±?3.07?mmol/L, P?
CONCLUSIONS: ? Combination therapy with metformin and mitiglinide is effective and safe for the treatment of patients with type 2 diabetes who have inadequate glycemic control with metformin monotherapy. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00023.x, 2010).
keyword
Metformin; Mitiglinide; Type 2 diabetes
¸µÅ©